Finn
DNLI Biotechnology · Rare disease · Neuroscience · Commercial launch · Thesis updated November 8, 2026

AVLAYAH launch outpaces estimates, shifting focus to sustained growth

01 Running thesis

Commercial launch accelerates

Denali has cleared its biggest near-term hurdle. The FDA approved AVLAYAH for neurologic signs of Hunter syndrome in March 2026. The drug generated $17.8 million in the third quarter, massively beating estimates due to rapid payer coverage expansion and trial patient rollovers. With a permanent J-code taking effect on October 1, the company guided for $30 million to $32 million in fourth-quarter sales.

The bull case is focused on this commercial execution. AVLAYAH early adoption has been stronger than expected, pulling forward the typical adoption curve. Priced between $270,000 and $800,000 per year depending on weight, the drug is establishing a revenue stream to fund Denali's other programs. The launch also provides real-world proof for Denali's Transport Vehicle platform, which carries large drugs across the blood-brain barrier. The company expects to file for approval of a second commercial product, DNL126, in 2027.

The bear case centers on maintaining momentum and pipeline delays. A large portion of early growth came from converting clinical trial patients. Management noted sequential growth will moderate as the launch shifts to a patient-by-patient adoption model. AVLAYAH also holds accelerated approval, meaning the FDA can require proof of benefit in a confirmatory study. If the ongoing COMPASS study fails, the product could be pulled.

The next year has several swing factors. Investors will watch AVLAYAH sales, the DNL126 data package and regulatory filing, the BIIB122 LUMA readout in Parkinson's disease, and DNL593 data in the first half of 2027.

Nov 2026▲AVLAYAH third-quarter sales reached $17.8 million, significantly beating guidance, while fourth-quarter revenue is expected to rise further. Denali also confirmed plans to file for DNL126 approval in 2027.
Aug 2026▲AVLAYAH generated $3.6 million in its first full commercial quarter with early demand exceeding expectations, and Denali sold its priority review voucher for $195 million. Clinical data for DNL593 was pushed to early 2027.
May 2026▲AVLAYAH received accelerated FDA approval, Denali received $200 million in gross proceeds from Royalty Pharma, and the FDA granted a priority review voucher. The positive shift is partly offset by Takeda's DNL593 termination.
Feb 2026▲Denali entered 2026 with an April 5 PDUFA date for tividenofusp alfa and a Royalty Pharma funding deal tied to approval. The D3X3 plan showed a clear push from platform validation toward commercial delivery.
Nov 2025→The FDA extended the tividenofusp alfa review timeline from January 5 to April 5, 2026 after asking for more clinical pharmacology information. The core setup stayed intact, but the decision moved later.
Aug 2025▲The FDA accepted the tividenofusp alfa BLA for priority review, giving Denali a January 5, 2026 target action date. Denali also aligned with the FDA on a surrogate endpoint that could support accelerated approval for DNL126.
May 2025▲Denali completed the rolling BLA submission for tividenofusp alfa. That moved the lead program from clinical proof toward FDA review and possible launch preparation.
Feb 2025▼The thesis became more concentrated in the ETV platform as DNL343 failed in ALS and several partnered programs were terminated. Tividenofusp alfa still offered a clear path to a BLA, but the rest of the pipeline looked riskier.
02 Business model

A drug delivery platform with a launched product

Denali's model starts with a hard problem. Many drugs cannot cross the blood-brain barrier, which is the body's natural shield around the brain. Its Transport Vehicle platform is designed to carry enzymes, proteins, antibodies, and oligonucleotides into the brain after intravenous dosing.

The company now earns revenue directly from AVLAYAH product sales, logging $17.8 million in the third quarter of 2026. It also earns collaboration revenue from partners like Sanofi and Biogen.

Funding also comes from alternative sources. Royalty Pharma agreed to provide up to $275 million in funding for a 9.25 percent royalty on future AVLAYAH sales, and Denali received $200 million of that in March 2026. In July 2026, the company sold its priority review voucher for $195 million, significantly strengthening its balance sheet.

The weak point is reliance on third parties. Denali needs a smooth rare disease launch, successful follow-up trials, and partner support for major programs. Takeda's exit from the DNL593 program shows that partners can leave even after a drug reaches human testing.

03 Product portfolio

What Denali is selling and proving

Growth engine

AVLAYAH, tividenofusp alfa-eknm

AVLAYAH is Denali's first approved product. It treats neurologic manifestations in Hunter syndrome and generated $17.8 million in the third quarter of 2026.

Option

DNL126, ETV:SGSH

DNL126 is an enzyme therapy for Sanfilippo syndrome Type A. Denali is targeting a biological license application for accelerated approval in 2027.

Option

BIIB122, DNL151

BIIB122 is a LRRK2 inhibitor for Parkinson's disease partnered with Biogen. Phase 2b LUMA data are expected in mid-2026.

Option

Eclitasertib, SAR443122/DNL758

Eclitasertib is a peripheral RIPK1 inhibitor for ulcerative colitis partnered with Sanofi. A Phase 2 data readout is expected in the first half of 2026.

Option

DNL593, PTV:PGRN

DNL593 is a progranulin therapy for frontotemporal dementia. Interim data is expected in the first half of 2027.

Option

DNL952, ETV:GAA

DNL952 is an enzyme therapy for Pompe disease. A Phase 1 study is moving ahead.

Option

DNL628 and DNL921

These are early-stage therapies for Alzheimer's disease. Data is expected for both in 2027.

04 Business segments

One reported business

Discovery and development of therapeutics100%modest
Other reported segments0%flat

Denali reports one operating and reportable segment for the discovery and development of therapeutics. The company recognizes product revenue from AVLAYAH alongside collaboration revenue.

05 Risk factors

What could break the thesis

Sustaining AVLAYAH growth

High impact · Medium odds

AVLAYAH sales started exceptionally well due to clinical trial rollovers and highly engaged patients. The growth rate could slow significantly as the launch shifts to a patient-by-patient adoption model.

We watchFourth-quarter AVLAYAH sales guidance of $30 million to $32 million and new patient starts.

Confirmatory trial failure

High impact · Medium odds

AVLAYAH was approved through the accelerated pathway, which allows earlier approval based on evidence expected to predict benefit. Denali still needs confirmatory evidence. If the COMPASS study does not support benefit, the FDA could require label limits or withdrawal.

We watchUpdates from the Phase 2/3 COMPASS confirmatory study set to end in late 2027.

Partner exits keep spreading

High impact · Medium odds

Takeda ended the DNL593 collaboration in April 2026. That followed other recent partner exits, including Sanofi's CNS RIPK1 license termination and Takeda's ATV:TREM2 termination. More partner pullbacks would raise the cost for Denali and hurt trust in the pipeline.

We watchBiogen's support for BIIB122 and Sanofi's support for eclitasertib.

Pipeline data disappoints

High impact · Medium odds

Neurodegenerative drug trials fail often. Denali has already seen DNL343 fail in ALS and several partnered programs stop. If BIIB122, DNL126, DNL593, or eclitasertib miss, the company could look too dependent on one rare disease product.

We watchThe Phase 2b LUMA Parkinson's readout, eclitasertib ulcerative colitis data, and DNL593 interim data.
06 Quick answers

In one breath

What does Denali Therapeutics do?

Denali develops drugs for neurodegenerative and lysosomal storage diseases. Its main technology is the Transport Vehicle platform, which is designed to help large drugs cross into the brain.

Is Denali Therapeutics now a commercial company?

Yes. The FDA approved AVLAYAH in March 2026, and the company generated $17.8 million in sales during the third quarter. However, most of its pipeline remains in clinical testing.

Why does AVLAYAH matter so much?

AVLAYAH is Denali's first approved drug and the first real commercial test of its platform. Strong sales support the bull case and help fund the rest of the company's research.

What happened to the priority review voucher?

The FDA granted Denali a rare pediatric disease priority review voucher when AVLAYAH was approved. In July 2026, Denali successfully sold the voucher for $195 million.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Denali Therapeutics Q3 2026 Earnings Transcript
  2. Denali Therapeutics Q2 2026 Earnings Transcript
  3. Denali Therapeutics Q1 2026 Form 10-Q
  4. Denali Therapeutics 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Denali Therapeutics Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today